Thromboprophylaxis for COVID-19-related coagulopathy: what next?

Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):E18-E19. doi: 10.1093/ehjcvp/pvac009.

Authors

Viktor Čulić^{1

2}, Riccardo Vio³, Riccardo Proietti⁴

Affiliations

¹ Department of Cardiology and Angiology, University Hospital Centre Split, Šoltanska 1, 21000 Split, Croatia.
² Department of Clinical Propedeutics, University of Split School of Medicine, Split, Croatia.
³ Cardiology Unit, Department of Cardiothoracic and Vascular Medicine, Ospedale dell'Angelo, Venice, Italy.
⁴ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anticoagulants / administration & dosage
Anticoagulants / adverse effects
Blood Coagulation
COVID-19*
Humans
Randomized Controlled Trials as Topic
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / drug therapy
Venous Thromboembolism* / prevention & control

Substances

Anticoagulants